Leone Lays Out Research Needs and Treatment Approaches in Male Breast Cancer
December 1st 2022Dr Leone discusses the distinguishing features of male breast cancer, the benefits and limitations of current treatments, and the importance of raising awareness about this breast cancer subset to propel further research.
Read More
Florez Discusses Crucial Aspects of Cancer Care Equity and Survivorship
November 28th 2022Dr Florez discusses why cancer care equity and survivorship should be a priority for all physicians, the steps the health care system needs to take to address disparities in these areas, and specific ways that Dana-Farber is working to close these gaps.
Read More
FDA Approval Insights: Durvalumab Plus Tremelimumab in HCC
November 24th 2022Dr Abou-Alfa discusses the FDA approval of durvalumab plus tremelimumab in unresectable hepatocellular carcinoma, the regimen’s unique mechanism of action, and the importance of expanding global access to this combination.
Read More
Crane Helps Gynecologic Fellows Deliver Care in a Complicated Time
November 21st 2022Dr Crane discusses why Atrium Health decided to launch a gyn onc fellowship, how she helps fellows navigate the current political landscape while maintaining high-level care, and how she tries to model a good work-life balance for her trainees.
Read More
Oppong Sheds Light on Racial Disparities in Breast Cancer Diagnosis and Mortality
November 17th 2022Dr Oppong discusses factors that contribute to the ongoing disparity in breast cancer deaths among Black women vs White women, the importance of increased access to high-quality screening, and the need for more inclusive research efforts to close the gaps in breast cancer diagnosis and care.
Read More
FDA Approval Insights: Teclistamab in Relapsed/Refractory Multiple Myeloma
November 14th 2022Dr Garfall discusses the FDA approval of teclistamab in relapsed/refractory multiple myeloma, key efficacy and safety data from the MajesTEC-1 trial, and the drug’s unique mechanism of action compared with other anti-myeloma agents.
Read More
Lunning Lends Insight on Pivotal Data From Pan Pacific Lymphoma 2022
November 10th 2022In this inaugural episode, Dr Lunning details important findings to come out of the Pan Pacific Lymphoma Conference, including results evaluating prophylactic medications in the management of patients with hematologic malignancies receiving cellular therapy or autologous stem cell transplant.
Read More
FDA Approval Insights: Futibatinib in FGFR2-Positive Cholangiocarcinoma
November 3rd 2022Dr Goyal discusses the FDA approval of futibatinib in FGFR2-positive cholangiocarcinoma, key safety data from the FOENIX*-CCA2 trial, and the importance of biomarker testing in the cholangiocarcinoma population.
Read More
Practices Should Refocus Efforts on Helping Patients Address Financial Toxicities
November 2nd 2022Optimizing clinical pathways to address financial toxicities faced by patients with cancer requires a complex, multifaceted approach. However, even small in-practice changes may ease the financial burdens and improve outcomes.
Read More
Thymic Cancer Experts Discuss the Latest Data, Need for More Research Funding
October 31st 2022Drs Giaccone and He discuss the implications of their thymic cancer research, the importance of combining immunotherapy and anti-angiogenesis agents to treat solid tumors, and the challenges of investigating rare cancers.
Read More
Mikhael and Cole Share Insights on Culturally Relevant Myeloma Care
October 27th 2022Drs Mikhael and Cole discuss ways to help reduce disparities in myeloma by delivering culturally relevant care and highlight the importance of implementing shared decision-making, creating a well-informed multidisciplinary staff, and meeting patients where they are.
Read More
FDA Approval Insights: Sodium Thiosulfate in Cisplatin-Treated Pediatric Solid Tumors
October 24th 2022Dr Shah discusses the FDA approval of sodium thiosulfate in pediatric patients with solid tumors treated with cisplatin, key efficacy and safety data from the SIOPEL6 and COG ACCL0431 trials, and the importance of multidisciplinary communication when prescribing and administering the agent.
Read More
Leukemia Experts Discuss Early Career Growth, Mentorship, and Gender Bias in Academia
October 20th 2022Drs DiNardo, Wang, and Altman discuss the challenges they faced in their early careers, the rollout of molecular profiling and targeted therapy in the early 2000s, and their growth from protégés to mentors.
Read More
Community Perspectives on Integrating and Interpreting Molecular Testing Results in NSCLC
October 17th 2022Drs Ramkumar and Morganstein discuss the challenges they face with integrating and organizing molecular testing results into electronic medical records, how they address non–small cell lung cancer test results with patients, and their hopes for the future of pathology at their institutions.
Read More
FDA Approval Insights: Durvalumab Plus Gemcitabine and Cisplatin in Biliary Tract Cancer
October 3rd 2022Dr Oh discusses the FDA approval of durvalumab plus gemcitabine and cisplatin in biliary tract cancer, the tolerability of the regimen, and the importance of using immunotherapy to treat this disease.
Read More
Shepard Discusses Symptoms, Management, and Future Directions in Desmoid Tumors
September 29th 2022Dr Shepard discusses the unpredictable course of desmoid tumors, the use of TKIs for these tumors, and findings from 2 trials presented at the 2022 ESMO Congress that may represent new treatment options for patients with desmoid tumors.
Read More
Patel Provides Insight Into Post-Transplant Complications in Myeloid Disorders
September 22nd 2022Dr Patel discusses post-transplant complications in myeloid disorders, the prevalence of these complications, and the most common ones that may arise, including primary disease relapse, graft-vs-host disease, infection, organ toxicity, persistent cytopenias, and immunosuppression.
Read More
FDA Approval Insights: Pemigatinib in FGFR1-Rearranged Myeloid/Lymphoid Neoplasms
September 19th 2022Dr Verstovsek discusses the FDA approval of pemigatinib in myeloid/lymphoid neoplasms with FGFR1 rearrangements, the transformative effects of pemigatinib, and the importance of identifying chromosomal abnormalities in patients with this aggressive disease.
Read More
Leal Sheds Light on Symptoms and Treatment of Lambert-Eaton Myasthenic Syndrome
September 15th 2022Dr Leal discusses the symptoms commonly associated with Lambert-Eaton Myasthenic Syndrome, the prevalence of this disorder in concurrence with underlying cancers, and how amifampridine can help manage this disease by improving motor and autonomic symptoms.
Read More
Chen Discusses Diagnosis, Management, and Disparities in Cutaneous T-cell Lymphoma
September 8th 2022Dr Chen details the findings from a study of patients with transformed cutaneous T-cell lymphoma, gives her perspective on findings from the FLASH trial, and discusses the need for more research funding in this disease.
Read More